-
-
Recent Posts
- Coronavirus today and the SCI community tomorrow
- Stroke Drug Boosts Stem Cell Therapy For Spinal Cord Injury In Rats
- An integrated in silico pipeline identifies a novel TF combination that promotes enhanced CST growth following injury
- Spike timing-dependent plasticity in the adult rat with chronic cervical spinal cord contusion
- Effect of PTEN antagonist peptide on the functional motor recovery in rat
- GDF10 promotes axonal regeneration and functional recovery: A novel gene therapy strategy for spinal cord injury
- GTX Medical and NeuroRecovery Technologies to merge
- Candidate Therapy From Quebec for Chronic SCI Being Developed in Parallel by Academics and Companies in Switzerland and the Netherlands
- Moving beyond the glial scar for spinal cord repair
- The Struggle to Make CNS Axons Regenerate: Why Has It Been so Difficult?
- The potential of electric field for promoting neurite guidance in spinal cord injury regeneration strategies
- Extraction and selective activation of muscle synergies through spinal stimulation for SCI
- Early limb unloading elicits long-term motor deficits involving motorneuron hyperexcitability associated with persistent alterations in glutamatergic synaptic plasticity in spinal cord injury
- The effects of a pro-angiogenic, RGD-functionalized, nanofiber composite biomaterial on mesenchymal stem cell-mediated repair of the injured spinal cord
- From wheelchair to walking after spinal cord injury
Follow on Twitter
My TweetsSpinal Cord Injury Research and Science at Facebook
Categories
Archives
Tag Archives: Neuralstem
Alliance for Regenerative Medicine (ARM) Neuralstem Presentation
Alliance for Regenerative Medicine (ARM) Neuralstem Presentation April 17, 2018 Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. The company’s lead asset and stem cell therapy candidate, NSI-566, is a … Continue reading
Posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, spinal cord injury research, Stem Cell Research
Tagged Alliance for Regenerative Medicine, Neuralstem
Comments Off on Alliance for Regenerative Medicine (ARM) Neuralstem Presentation
Induction of immune tolerance by short-course immunosuppresion after spinal grafting of allogeneic neural precursors in pigs with previous chronic spinal cord traumatic injury.
Current clinical protocols use transient or continuous immunosuppression in patients receiving allogeneic neural precursor grafts for treatment of a variety of neurological diseases, including spinal trauma, stroke or ALS. At present there is no solid evidence, however, that would confirm … Continue reading
Neuralstem flirting with stem cell noncompliance in Colorado via Right To Try Law?
I frequently check in to see what’s happening at the Paul Knoepfler Stem Cell blog. His post yesterday took me by complete surprise. Even though SCI isn’t part of the PTT Law, this will be an interesting situation to follow. … Continue reading
Posted in Regenerative Medicine
Tagged Neuralstem, Paul Knoepfler, Richard Garr
Comments Off on Neuralstem flirting with stem cell noncompliance in Colorado via Right To Try Law?
Neuralstem Spinal Cord Injury Stem Cell Trial Approved To Commence At University Of California, San Diego (NSI-566 to be Tested in Patients with Chronic Spinal Cord Injury)
Neuralstem, Inc. announced that the Institutional Review Board of the University of California, San Diego, School of Medicine has approved the Phase I safety trial to treat chronic spinal cord injury (cSCI) with its NSI-566 stem cells. The NSI-566/cSCI Phase … Continue reading
Posted in Chronic Spinal Cord Injury Research, spinal cord injury research, Stem Cell Research
Tagged Neuralstem
Comments Off on Neuralstem Spinal Cord Injury Stem Cell Trial Approved To Commence At University Of California, San Diego (NSI-566 to be Tested in Patients with Chronic Spinal Cord Injury)
Neuralstem: World Stem Cells & Regenerative Medicine Congress 2013
Richard Garr, President & CEO of Neuralstem gives his presentation on ‘Understanding the Practicalities of Using Innovative Therapies on Patients’ at the World Stem Cells & Regenerative Medicine Congress 2013.
Posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, spinal cord injury research, Stem Cell Research, Uncategorized
Tagged Neuralstem, Richard Garr
Comments Off on Neuralstem: World Stem Cells & Regenerative Medicine Congress 2013
Neuralstem Receives FDA Approval for Chronic SCI Trial
ROCKVILLE, Md., Jan. 14, 2013 /PRNewswire/ — Neuralstem, Inc. (NYSE MKT: CUR) announced that it received approval from the United States Food and Drug Administration (FDA) to commence a Phase I safety trial of its lead cell therapy candidate, NSI-566, … Continue reading
Posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, spinal cord injury research
Tagged chronic spinal cord injury, corticospinal tract, locomotion, motor function, Neuralstem, spinal cord injury research, stem cell biology, stem cells, U2FP, Unite 2 Fight Paralysis
Comments Off on Neuralstem Receives FDA Approval for Chronic SCI Trial
SPINAL CORD INJURY RESEARCH AND SCIENCE 